Sign In
Buy CMPS
$12.69
-0.640 (-4.80%)
At Close: Jun 03, 2026
Compass Pathways to announce first quarter financial results on May 8, 2024
04:58pm, Friday, 03'rd May 2024
LONDON, May 03, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced
LONDON, May 02, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental he
LONDON, April 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental
Compass Pathways to participate in upcoming 23rd Annual Needham Virtual Healthcare Conference
04:01pm, Monday, 01'st Apr 2024
LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announce
Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors
08:00am, Thursday, 28'th Mar 2024
David Norton Assumes Role of Interim Board Chair while the Company Runs a Global Search for a New Chair David Norton Assumes Role of Interim Board Chair while the Company Runs a Global Search for a Ne
3 Biopharma Stocks You Don't Want to Miss in the New Bull Market
09:30am, Tuesday, 05'th Mar 2024
Vertex Pharmaceuticals is angling to treat acute pain with its new drug. Compass Pathways will have a major data update sometime in Q4.
COMPASS Pathways plc (CMPS) Q4 2023 Earnings Call Transcript
11:43am, Thursday, 29'th Feb 2024
COMPASS Pathways plc (CMPS) Q4 2023 Earnings Call Transcript
Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights
07:00am, Thursday, 29'th Feb 2024
LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental h
Penny Power Players: 3 Stocks to Watch in the Microcap Arena
12:33pm, Tuesday, 27'th Feb 2024
There are some great microcap stocks for investors to scoop up this month. The broader indices, such as the S&P 500 and the Nasdaq, are showing signs of both strength and weakness, but I believe that
Compass Pathways to participate in upcoming TD Cowen investor conference
04:01pm, Monday, 26'th Feb 2024
LONDON, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced
Compass Pathways to announce fourth quarter and year-end 2023 financial results on February 29, 2024
04:01pm, Thursday, 22'nd Feb 2024
LONDON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced
Wall Street Says Compass Pathways Could Rise 307%. Here's How It Could Actually Happen.
07:00am, Monday, 19'th Feb 2024
Compass will report some critical clinical trial data this year. One of its peers could soon see its first drug approved.
Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play
05:15pm, Thursday, 08'th Feb 2024
Compass Pathways plc, a biotech company based in London, is developing a psilocybin-based therapy for CNS disorders. The company's shares declined by over 80% in 2022 due to safety concerns and regula
Compass Pathways to participate in upcoming Oppenheimer investor conference
04:01pm, Wednesday, 31'st Jan 2024
LONDON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced
